Results 71 to 80 of about 16,042 (257)

Promising Cancer Vaccine for Glioblastoma Therapy: A Focus on mRNA Vaccine

Cancer Medicine, Volume 14, Issue 18, September 2025.
ABSTRACT Background Glioblastoma (GBM) is an aggressive primary brain tumor with poor prognosis and low survival rates. Standard treatments, such as surgery and radiotherapy, are limited by tumor infiltration and resistance. To review current vaccine strategies for GBM, including peptide, virotherapy, cell‐based, and genetic vaccines, with a focus on ...
Sama Barati, Sahar Ghoflchi, Pejman Hosseinzadeh, Sobhan Pouramini, Hossein Hosseini, Mohammad Jalili‐Nik   +5 more
wiley   +1 more source

Comparative study of antibody levels developed by vaccination against polio virus in population after vaccine type alteration [PDF]

, 2015
During clinical trials, samples from Hungarian patients of different age groups were tested for antibodies against all 3 serotypes of poliovirus, a member of Picornaviridae family.
Farkas, Ágnes, Magyar, Nóra, Szomor, Katalin, Takács, Mária   +3 more
core   +1 more source

Promising Prodiginins Biological Activities

Chemistry &Biodiversity, Volume 22, Issue 9, September 2025.
ABSTRACT Prodiginins are a large family of at least 34 pyrrolic compounds, including the well‐studied red pigment prodigiosin. Prodiginins are produced by several microorganisms displaying broad biological activities, including antimicrobial, antiviral, antiparasitic, antiproliferative, and immunosuppressive activities.
María F. Ladetto, Melisa E. Gantner, Boris E. Rodenak‐Kladniew, Santiago Rodriguez, María L. Cuestas, Alan Talevi, Guillermo R. Castro   +6 more
wiley   +1 more source

Rectal Microbiome Composition Correlates with Humoral Immunity to HIV-1 in Vaccinated Rhesus Macaques. [PDF]

, 2019
The microbiome is an integral and dynamic component of the host and is emerging as a critical determinant of immune responses; however, its influence on vaccine immunogenicity is largely not well understood.
Dinasarapu, Ashok R, Durbin-Johnson, Blythe P, Elizaldi, Sonny R, Iyer, Smita S, Kozlowski, Pamela A, Raeman, Reben, Rolston, Matthew, Settles, Matthew, Verma, Anil, Walter, Korey A   +9 more
core   +1 more source

Natural Killer Cell‐Mediated Antitumor Immunity: Molecular Mechanisms and Clinical Applications

MedComm, Volume 6, Issue 9, September 2025.
NK cells eliminate tumors via cytotoxicity and cytokine secretion. Tumor microenvironment‐driven immunosuppression and metabolic reprogramming subvert NK cells’ cytotoxicity. The current clinical strategies to restore NK activity include ex vivo expansion for adoptive transfer, CAR‐NK engineering, TME‐remodeling agents, immune checkpoint blockade ...
Nanzhi Luo, Cong Chen, Wenjing Zhou, Jianqi Hao, Song He, Yu Liu, Yin Ku, Linhua Huang, Chuanfen Zhang, Yueli Shu, Xiaoqing Wu, Yaojia Zhou, Jian Zhang   +12 more
wiley   +1 more source

Polio control after certification: major issues outstanding

Bulletin of the World Health Organization, 2004
Now that the global eradication of wild poliovirus is almost within sight, planning for the post-certification era is becoming a priority issue. It is agreed that a stockpile of appropriate polio vaccines will need to be established, and a surveillance ...
Fine Paul E.M., Oblapenko George, Sutter Roland W.   +2 more
doaj  

Twenty-Eight Years of Poliovirus Replication in an Immunodeficient Individual: Impact on the Global Polio Eradication Initiative.

PLoS Pathogens, 2015
There are currently huge efforts by the World Health Organization and partners to complete global polio eradication. With the significant decline in poliomyelitis cases due to wild poliovirus in recent years, rare cases related to the use of live ...
Glynis Dunn, Dimitra Klapsa, Thomas Wilton, Lindsay Stone, Philip D Minor, Javier Martin   +5 more
doaj   +1 more source

Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization. [PDF]

, 2017
A fractional dose of inactivated poliovirus vaccine (fIPV) administered by the intradermal route delivers one fifth of the full vaccine dose administered by the intramuscular route and offers a potential dose-sparing strategy to stretch the limited ...
Chang Blanc, Diana, Gonzalez, Alejandro Ramirez, Jarrahian, Courtney, Macklin, Grace, Okayasu, Hiromasa, Sein, Carolyn, Sutter, Roland W, Zehrung, Darin   +7 more
core   +1 more source

Circulating Vaccine‐Derived Poliovirus Type 2 (cVDPV2) Outbreak Response With Novel Oral Poliovirus Vaccine Type 2 (nOPV2), Sierra Leone's Experience

Public Health Challenges, Volume 4, Issue 3, September 2025.
ABSTRACT Background In March 2024, a circulating vaccine‐derived poliovirus type 2 (cVDPV2) was isolated in environmental samples (ESs) collected at the Mabella Sawmill Bridge environmental surveillance (ES) site. The Ministry of Health and its partners responded to the outbreak by conducting a novel oral poliovirus vaccine type 2 (nOPV2) nationwide ...
Desmond M. Kangbai, Edwin N. Sesay, Nella Clemens‐Kangbai, Andrew K. Kemoh, Sallu Lansana, Hassan Benya, Aminata Nunie, Joyce M. Kallon, Edna G. Samuels, Amanda Clemens, Michael Jones, Braima Patrick Kanneh, Peter B. James, Andrew Alfred Nyakeh Jimmy, Mohamed T. M. Kallay, Tom Sesay   +15 more
wiley   +1 more source

Determination of Factors Affecting Bivalent (Type 1 and 3) Stability of Oral Poliomyelitis Vaccine

Medical Laboratory Journal, 2020
Background and objectives: After using of trivalent oral poliovirus vaccine (OPV) for a long time in Iran, in recent years, due to the eradication of type 2 of poliovirus, a bivalent vaccine containing types 1 and 3 is used.
Sina Soleimani
doaj